Patent: 10,182,969

Summary for Patent: 10,182,969

Title:	Aseptic piercing system and method
Abstract:	The present disclosure provides aseptic vial piercing and sterilization systems, and methods of assembling, using and sterilizing same. The systems and methods utilize a pre-sterilized primary container including a first end, a first cavity, a second end with an opening in communication with the first cavity, a septum at least partially sealing the opening, and a product within the first cavity. The systems and methods include an injection assembly including a first end portion of a hollow flowpath forming member. The injection assembly and the primary container may be assembled in a non-sterile environment to form a second cavity extending about the first end portion of the flowpath forming member and to the primary container. The second cavity may then be selectively sterilized in a non-deleterious manner to the product to allow the first end portion to aseptically pierce the septum to extend into the first cavity.
Inventor(s):	Rachel Paige Arnott, Bart E. BURGESS, Michael Cupicha, Alexei Goraltchouk, Bryan Grygus, Mike Stelmah
Assignee:	Regeneron Pharmaceuticals Inc
Application Number:	US15/066,791
Patent Claims:	see list of patent claims

Details for Patent 10,182,969

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	18-Nov-11	10,182,969	2036-03-10
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	16-Aug-18	10,182,969	2036-03-10
Regeneron Pharmaceuticals, Inc.	EYLEA HD	aflibercept	Injection	761355	18-Aug-23	10,182,969	2036-03-10

International Patent Family for US Patent 10,182,969

Country	Patent Number	Estimated Expiration
Australia	2016228990
Australia	2020220127
Australia	2022291593
Australia	2025204036